华宝基金240010. 华宝基金240010VROBIO Inc公司介绍
| 证券代码： |
AVRO |
上市板： |
主板 |
| 证券名称： |
AVROBIO Inc |
上市场所： |
纳斯达克交易所 |
| 证券类型： |
普通股 |
发行方式： |
公开发售 |
| 首发上市日： |
2018/06/21 |
首发价格(元)： |
19 |
| 首发数量(股)： |
5,247,958 |
首发募资总额(USD/元)： |
99,711,202.00 |
AVROBIO Inc基本资料
| 公司名称： |
AVROBIO, Inc. |
注册地址： |
美国特拉华州 |
| 证券名称： |
AVROBIO Inc |
上市场所： |
纳斯达克交易所 |
| 办公地址： |
One Kendall Square, Buildin 华宝基金240010g 300, Suite 201, Ca 华宝基金240010mbridge, Massachusetts, USA |
| 董事会主席： |
- |
成立日期： |
2015/11/01 |
| 公司属地： |
United States 美国 |
电话： |
+1 (617) 914-8420 |
| 公司网址： |
www.avrobio.com |
| 公司介绍： |
AVROBIO, Inc. is a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. It believes that its approach has the potential to provide curative benefit in an outpatient setting for a range of diseases. Its initial focus is on a group of rare genetic diseases referred to as lysosomal storage diseases, which today are primarily managed with enzyme replacement therapies, or ERTs. These lysosomal storage diseases have well understood biologies, identified patient populations and represent large market opportunities with approximately $4.0 billion in worldwide net sales in 2017. |
本文来自投稿，不代表本人立场，如若转载，请注明出处：http://www.smctrader.com/zhengquangongsi/91256.html
标签：
AVRO
AVRO基金净值
AVROBIO Inc股票代码
AVRO股票
AVROBIO Inc公司概况
AVRO股吧
AVRO股票行情
AVROBIO Inc公司档案